Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 70, Issue 5, 2004, Pages 479-483

  Mohammed, S I ^a   Khan, K N M ^b   Sellers, R S ^b   Hayek, M G ^c   DeNicola, D B ^a   Wu, L ^a   Bonney, P L ^a   Knapp, D W ^a  

^a PURDUE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c IAMS COMPANY   (United States)

Author keywords

Canine; Cyclooxygenase; Tumors

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CONTROLLED STUDY; DOG; EVALUATION; FIBROSARCOMA; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOMA; MELANOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANIMALIA;

EID: 0942285260     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.10.002     Document Type: Article

References (33)

1. G.S. Geis, Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand. J. Rheumatol. Suppl. 109 (1999) 31-37.
2. G. Dannhardt, W. Kiefer, Cyclooxygenase inhibitors - current status and future prospects, Eur. J. Med. Chem. 36 (2001) 109-126.
3. J.B. Raskin, Gastrointestinal effects of nonsteroidal anti-inflammatory therapy, Am. J. Med. 106 (5B) (1999) 3S-12S.
4. H. Yoshida, Y. Fukumura, S. Fujita, M. Nishida, T. Iizuka, The distribution of cyclooxygenase-1 in human temporomandibular joint samples: an immunohistochemical study, Oral Rehabil. 28 (2001) 511-516.
5. G. Halliday, S.R. Robinson, C. Shepherd, J. Kril, Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms, Clin. Exp. Pharmacol. Physiol. 27 (2000) 1-8.
6. W.J. Lukiw, N.G. Bazan, Neuroinflammatory signaling upregulation in Alzheimer's disease, Neurochem. Res. 25 (2000) 1173-1184.
7. Y.H. Lee, S.H. Choi, A. Kim, C.H. Kim, J.D. Ji, G.G. Song, Expression of cyclooxygenase-1 and -2 in rheumatoid arthritis synovium, J. Korean Med. Sci. 15 (2000) 88-92.
8. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, R.N. DuBois, Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas, Gastroenterology 107 (1994) 1183-1188.
9. R.A. Soslow, A.J. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, J. Masferrer, A.T. Koki, COX-2 is expressed in human pulmonary, colonic, and mammary tumors, Cancer 89 (12) (2000) 2637-2645.
10. S.I. Mohammed, D.W. Knapp, D.G. Bostwick, et al., Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder, Cancer Res. 59 (1999) 5647-5650.
11. K.N. Khan, D.W. Knapp, D.B. Denicola, R.K. Harris, Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs, Am. J. Vet. Res. 61 (2000) 478-481.
12. M.F. McEntee, J.M. Cates, N. Neilsen, Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs, Vet. Pathol. 39 (2002) 428-436.
13. C. Tremblay, M. Dore, P.N. Bochsler, J. Sirois, Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma, J. Natl. Cancer Inst. 91 (1999) 1398-1403.
14. M. Dore, I. Lanthier, J. Sirois, Cyclooxygenase-2 expression in canine mammary tumors, Vet. Pathol. 40 (2003) 207-212.
15. A. Lupulescu, Prostaglandins, their inhibitors and cancer, Prostaglandins Leukot. Essent. Fatty Acids 54 (1996) 83-94.
16. G. Ara, B.A. Teicher, Cyclooxygenase and lipoxygenase inhibitors in cancer therapy, Prostaglandins Leukot. Essent. Fatty Acids 54 (1996) 3-16.
17. Y. Furuta, E.R. Hall, S. Sanduja, T. Barkley Jr., L. Milas, Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin, Cancer Res. 48 (1988) 3002-3007.
18. L.J. Marnett, Aspirin, the potential role of prostaglandins in colon cancer, Cancer Res. 52 (1992) 5575-5589.
19. D.L. Earnest, L.J. Hixson, D.S. Alberts, Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention, J. Cell. Biochem. Suppl. 161 (1992) 156-166.
20. S.I. Mohammed, K. Coffman, N.W. Glickman, et al., Prostaglandin E2 concentrations in naturally occurring canine cancer, Prostaglandins Leukot. Essent. Fatty Acids 64 (2001) 1-4.
21. W. Dempke, C. Rie, A. Grothey, H.J. Schmoll, Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 127 (2001) 411-417.
22. S.I. Mohammed, P.F. Bennett, B.A. Craig, et al., Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer, Cancer Res. 62 (2) (2002) 356-358.
23. L.A. Garcia Rodriguez, S. Hernandez-Diaz, F.J. de Abajo, Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies, Br. J. Clin. Pharmacol. 52 (2001) 563-571.
24. J.E. Castelao, J.M. Yuan, M. Gago-Dominguez, M.C. Yu, R.K. Ross, Non-steroidal anti-inflammatory drugs and bladder cancer prevention, Br. J. Cancer 82 (7) (2000) 1364-1369.
25. D.W. Knapp, R.C. Richardson, G.D. Bottoms, R. Teclaw, T.C. Chan, Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors, Cancer Chemother. Pharmacol. 29 (1992) 214-218.
26. D.W. Knapp, R.C. Richardson, T.C. Chan, et al., Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder, J. Vet. Intern. Med. 8 (4) (1994) 273-278.
27. D.W. Knapp, D.J. Waters, Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans, Mol. Med. Today 3 (1997) 8-11.
28. J.K. Gierse, N.R. Staten, G.F. Casperson, et al., Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2, Vet. Ther. 3 (2002) 270-280.
29. E.M. Pestili de Almeida, C. Piche, J. Sirois, M. Dore, Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs, J. Histochem. Cytochem. 49 (2001) 867-875.
30. B.R. Schmidt, N.W. Glickman, D.B. DeNicola, A.E. de Gortari, D.W. Knapp, Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs, J. Am. Vet. Med. Assoc. 218 (2001) 1783-1786.
31. P.A. Boria, D.J. Murry, P. Bennett, N.W. Glickman, P.W. Snyder, B. Merkel, D. Schlittler, A.J. Mutsaers, R. Thomas, P. Bonney, D.W. Knapp, Phase I/II clinical trial of cisplatin/ piroxicam in canine oral cancer, J. Vet. Intern. Med., 2003, accepted for publication.
32. S.I. Mohammed, B.A. Craig, A.J. Mutsaers, et al., Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer, Mol. Cancer Ther. 2 (2003) 183-188.
33. A.J. Mutsaers, N.W. Glickman, D.B. DeNicola, et al., Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs, J. Am. Vet. Med. Assoc. 220 (2002) 1813-1817.